PALB2 rs515726065: Understanding This Rare Genetic Variant
The rs515726065 variant is a rare, pathogenic genetic change located within the PALB2 gene. It is associated with an increased risk for certain hereditary cancers, including breast and pancreatic cancer, by disrupting the body's ability to repair DNA.
What each genotype means
Typical PALB2 genetic profile
This genotype represents the most common sequence found in the general population for this specific location in the PALB2 gene. It is not associated with the increased cancer risks linked to pathogenic variants in this gene. Individuals with this profile do not have the specific genetic alteration described in the catalog.
This is the most common genotype observed across all global populations.
Increased cancer risk carrier
This genotype indicates the presence of one copy of the variant, which is associated with an increased risk for certain hereditary cancers, including breast and pancreatic cancer. Because PALB2 is a gene linked to cancer predisposition, individuals with this result should consult with a genetic counselor or healthcare provider to discuss personalized screening and risk management strategies.
This genotype is rare, occurring in a very small percentage of the population.
Elevated cancer risk profile
This genotype indicates the presence of two copies of the variant, which is associated with a significantly increased risk for hereditary cancer syndromes. It is important to discuss these findings with a medical professional or genetic specialist to understand the implications for long-term health and to review appropriate clinical surveillance options.
This genotype is extremely rare in the general population.
What is the rs515726065 Variant?
The variant rs515726065, often referred to in literature as c.509_510del or p.Arg170fs, is a specific deletion of two nucleotides within the PALB2 gene. Located on chromosome 16, this deletion causes a frameshift mutation, which alters the way the genetic code is read. This change typically results in a premature stop signal during protein synthesis, leading to the production of a truncated, non-functional protein. Because the PALB2 protein is essential for maintaining genomic stability, the loss of its function can have significant biological consequences. This variant is classified as pathogenic, meaning it is known to disrupt normal gene function and is linked to increased health risks in individuals who carry it.
The Role of the PALB2 Gene
The PALB2 gene, which stands for 'Partner and Localizer of BRCA2,' plays a critical role in the body's DNA repair machinery. It acts as a bridge between the BRCA1 and BRCA2 proteins, helping them work together to repair damaged DNA through a process called homologous recombination. This pathway is vital for fixing double-strand breaks in DNA, which can occur during normal cell division or due to environmental stressors. When the PALB2 gene is functioning correctly, it helps prevent the accumulation of mutations that could lead to uncontrolled cell growth. When a pathogenic variant like rs515726065 prevents the production of a functional protein, the cell's ability to repair its DNA is compromised, which can increase the likelihood of developing certain types of cancer.
Research and Cancer Associations
Scientific research has established a strong link between pathogenic variants in PALB2 and an elevated risk of several cancers. Studies, including large international analyses of families with PALB2 variants, have confirmed that carriers face a significantly higher risk of female breast cancer compared to the general population. There is also evidence of increased risks for pancreatic cancer, ovarian cancer, and male breast cancer. The strength of these associations is considered robust, leading many clinical guidelines to include PALB2 in genetic testing panels for hereditary cancer syndromes. While the risk is elevated, it is important to note that carrying a pathogenic variant does not guarantee that an individual will develop cancer; rather, it indicates a higher susceptibility that may warrant personalized screening and management strategies.
Population Frequency
The rs515726065 variant is considered rare in the general population. Data from large-scale genomic databases, such as gnomAD, indicate that this specific deletion is found at a very low frequency across diverse ancestral groups. In some regions, particularly in Central and Eastern Europe, this variant has been identified as a 'founder mutation,' meaning it is more common in specific populations due to historical demographic factors. Because it is rare, most individuals will not carry this variant. Its presence is typically identified through clinical genetic testing, often performed after a personal or family history of cancer has been documented, rather than through routine population-wide screening.
Managing Genetic Information
If you or a family member have been identified as a carrier of the rs515726065 variant, it is essential to consult with a certified genetic counselor or a healthcare provider specializing in oncology. This information is not a diagnosis of cancer, but it is a tool that can help you and your medical team make informed decisions about your health. You cannot change your genetic sequence, but you can take proactive steps, such as participating in enhanced cancer surveillance or discussing risk-reduction strategies with your doctor. Avoid making medical decisions based solely on online information. Always work with a clinical professional who can interpret your specific results in the context of your personal and family medical history.
How common is this variant?
The rs515726065 variant is rare in the general population, with a low overall allele frequency reported in large databases like gnomAD.
Frequently asked questions
What does it mean to have a PALB2 mutation?
Having a pathogenic PALB2 mutation means that one of your two copies of the PALB2 gene is not functioning correctly. This can impair your body's ability to repair DNA, which is associated with an increased risk of developing certain cancers.
Does having the rs515726065 variant mean I will get cancer?
No, having this variant does not mean you will definitely develop cancer. It indicates a higher susceptibility compared to the general population, but many factors, including lifestyle and other genetic influences, contribute to cancer risk.
Should I get tested for this variant?
Genetic testing is typically recommended for individuals with a personal or strong family history of breast, pancreatic, or ovarian cancer. You should discuss the appropriateness of testing with a genetic counselor or your physician.
What should I do if I am a carrier?
If you are a carrier, you should consult with a genetic counselor or an oncologist to discuss a personalized health management plan. This may include more frequent cancer screenings or other preventive measures tailored to your risk profile.
Sources & further reading
Educational information only, last refreshed 10/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs515726065?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29